<DOC>
	<DOCNO>NCT01789957</DOCNO>
	<brief_summary>This multicenter , open-label extension study Protocol 2993-112 design ass long-term glucose control measure HbA1c ( glycosylated hemoglobin ) evaluate long-term safety tolerability subject treat metformin receive subcutaneously inject AC2993 ( 10 mcg ) administer twice daily . Subjects complete Protocol 2993-112 eligible enroll .</brief_summary>
	<brief_title>Extension Study 2993-112</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>All following criterion fulfil inclusion individual study unless sponsor grant exception : Has complete 30week tripleblind treatment initiation/active treatment period Protocol 2993112 , include procedure require study termination visit ( Week 30 ) . Male female . Female individual must either 1 ) postmenopausal document serum FSH measurement unless use estrogen hormone replacement therapy ; 2 ) childbearing potential used appropriate contraceptive method ( surgical sterility oral , injected , barrier , intrauterine , implanted contraceptive ) duration Protocol 2993112 . This individual must current , negative pregnancy test ( human chorionic gonadotropin [ HCG ] , beta subunit ) regardless birth control method use . The individual agrees continue use birth control throughout study prevent pregnancy . Able understand sign Protocol 2993112Especific inform consent form , communicate investigator , understand comply protocol requirement . Individuals meet follow criterion exclude study unless sponsor grant exception : Has complete Protocol 2993112 . Female individual pregnant , lactating , plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>